{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T12:47:14Z","timestamp":1722689234402},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,17]]},"DOI":"10.7759\/cureus.22340","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T23:53:32Z","timestamp":1645142012000},"source":"Crossref","is-referenced-by-count":0,"title":["Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga"],"prefix":"10.7759","author":[{"given":"Krishna","family":"Baradhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen SS","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009, 160:491-7. 10.1530\/EJE-08-0818","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012286551-0\/50027-0","article-title":"Familial hypophosphatemia and related disorders","author":"Holm IA","year":"2003","unstructured":"Holm IA, Econs MJ, Carpenter TO. Familial hypophosphatemia and related disorders. Pediatric Bone: Biology and Diseases. Glorieux FH, Juppner H, Pettifor JM (ed): Academic Press, San Diego, CA; 2003. 603-31. 10.1016\/B978-012286551-0\/50027-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets","volume":"11","author":"Francis F","year":"1995","unstructured":"Francis F, Hennig S, Korn B, et al.. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet. 1995, 11:130-6. 10.1038\/ng1095-130","journal-title":"Nat Genet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa I","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, et al.. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006, 444:770-4. 10.1038\/nature05315","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada T","year":"2004","unstructured":"Shimada T, Kakitani M, Yamazaki Y, et al.. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004, 113:561-8. 10.1172\/JCI19081","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507043130101","article-title":"Calcification of entheses associated with X-linked hypophosphatemic osteomalacia","volume":"313","author":"Polisson RP","year":"1985","unstructured":"Polisson RP, Martinez S, Khoury M, et al.. Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med. 1985, 313:1-6. 10.1056\/NEJM198507043130101","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.195.3.7754003","article-title":"Chiari I malformation: association with hypophosphatemic rickets and MR imaging appearance","volume":"195","author":"Caldemeyer KS","year":"1995","unstructured":"Caldemeyer KS, Boaz JC, Wappner RS, Moran CC, Smith RR, Quets JP. Chiari I malformation: association with hypophosphatemic rickets and MR imaging appearance. Radiology. 1995, 195:733-8. 10.1148\/radiology.195.3.7754003","journal-title":"Radiology"},{"key":"ref8","article-title":"X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults","volume":"68","author":"Reid IR","year":"1989","unstructured":"Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore). 1989, 68:336-52.","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0199","article-title":"Hypertension is a characteristic complication of X-linked hypophosphatemia","volume":"64","author":"Nakamura Y","year":"2017","unstructured":"Nakamura Y, Takagi M, Takeda R, Miyai K, Hasegawa Y. Hypertension is a characteristic complication of X-linked hypophosphatemia. Endocr J. 2017, 64:283-9. 10.1507\/endocrj.EJ16-0199","journal-title":"Endocr J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-002-1044-6","article-title":"Hypertension in hypophosphatemic rickets\u2014role of secondary hyperparathyroidism","volume":"18","author":"Alon US","year":"2003","unstructured":"Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O. Hypertension in hypophosphatemic rickets\u2014role of secondary hyperparathyroidism. Pediatr Nephrol. 2003, 18:155-8. 10.1007\/s00467-002-1044-6","journal-title":"Pediatr Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge CF","year":"1991","unstructured":"Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med. 1991, 325:1843-8. 10.1056\/NEJM199112263252604","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.78.6.8200940","article-title":"Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia","volume":"78","author":"Carpenter TO","year":"1994","unstructured":"Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL. Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab. 1994, 78:1378-83. 10.1210\/jcem.78.6.8200940","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2018.1435115","article-title":"Scurvy in 2017 in the USA","volume":"31","author":"Baradhi KM","year":"2018","unstructured":"Baradhi KM, Vallabhaneni S, Koya S. Scurvy in 2017 in the USA. Proc (Bayl Univ Med Cent). 2018, 31:227-8. 10.1080\/08998280.2018.1435115","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02411222","article-title":"Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia","volume":"34","author":"Lyles KW","year":"1982","unstructured":"Lyles KW, Clark AG, Drezner MK. Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia. Calcif Tissue Int. 1982, 34:125-30. 10.1007\/BF02411222","journal-title":"Calcif Tissue Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.570","article-title":"Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia","volume":"56","author":"Zhang X","year":"2016","unstructured":"Zhang X, Imel EA, Ruppe MD, et al.. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol. 2016, 56:176-85. 10.1002\/jcph.570","journal-title":"J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter TO","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, et al.. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018, 378:1987-98. 10.1056\/NEJMoa1714641","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte MP","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019, 7:189-99. 10.1016\/S2213-8587(18)30338-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna KL","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, et al.. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018, 33:1383-93. 10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10074","article-title":"First-in-Asian phase I study of the anti-fibroblast growth factor 23 monoclonal antibody, burosumab: safety and pharmacodynamics in adults with X-linked hypophosphatemia","volume":"3","author":"Cheong HI","year":"2019","unstructured":"Cheong HI, Yoo HW, Adachi M, et al.. First-in-Asian phase I study of the anti-fibroblast growth factor 23 monoclonal antibody, burosumab: safety and pharmacodynamics in adults with X-linked hypophosphatemia. JBMR Plus. 2019, 3:e10074. 10.1002\/jbm4.10074","journal-title":"JBMR Plus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/86747-dramatic-transformation-after-burosumab-in-a-young-boy-with-x-linked-hypophosphatemia-a-life-changing-saga","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:17Z","timestamp":1707507977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/86747-dramatic-transformation-after-burosumab-in-a-young-boy-with-x-linked-hypophosphatemia-a-life-changing-saga"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.22340","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}